Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
ONCY Stock Chart & Stats
$1.05
-$0.03(-3.70%)
At close: 4:00 PM EST
$1.05
-$0.03(-3.70%)
Day’s Range― - ―
52-Week Range$0.33 - $1.51
Previous CloseN/A
Volume216.96K
Average Volume (3M)1.85M
Market Cap
$112.99M
Enterprise Value$132.53M
Total Cash (Recent Filing)$12.35M
Total Debt (Recent Filing)$835.00K
Price to Earnings (P/E)―
Beta0.84
Next Earnings
May 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding107,606,380
10 Day Avg. Volume1,395,505
30 Day Avg. Volume1,847,326
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)16.80
Price to Sales (P/S)0.00
P/FCF Ratio-3.69
Enterprise Value/Market Cap1.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.74
Forecast
1Y Price Target
$6.67Price Target Upside535.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$856.26K
Bulls Say, Bears Say
Bulls Say
Clinical Activity And MechanismEarly clinical and translational data show pelareorep can replicate in tumors, stimulate immune activation, and produce higher objective response rates and durable remissions in heavily pretreated patients, supporting its potential as a multi-indication immunotherapy.
Pivotal Study And FDA AlignmentClear FDA alignment on pivotal Phase 3 design, including a survival-based primary endpoint and confirmation that pelareorep plus chemotherapy could support a Biologics License Application if successful, materially de-risks the registrational path.
Regulatory DesignationFDA granted Fast Track Designation to pelareorep for second-line KRAS‑mutant metastatic colorectal cancer with microsatellite‑stable disease, enabling advancement to a randomized trial and signaling regulatory recognition of the therapy's potential.
Bears Say
Commercialization And Valuation RiskAnalyst valuation applies substantial clinical and commercialization risk adjustments, reflecting uncertainty around broader efficacy, competitive dynamics, and future reimbursement and revenue outcomes.
Financing And Dilution RiskAnticipated equity raises to fund clinical development could dilute existing shareholders and slow progress toward analyst price objectives if capital needs grow.
Limited Patient Data UncertaintyEfficacy signals are derived from small patient cohorts, creating uncertainty that requires confirmation in larger, controlled registration trials before broad adoption can be assumed.
Oncolytics Biotech News
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.33 and its highest was $1.51 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $112.99M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is May 01, 2026 which is in 55 days.
How were Oncolytics Biotech’s earnings last quarter?
Currently, no data Available
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 107,606,380 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oncolytics Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (535.24% Upside)
$6.67 (535.24% Upside)
Blogger Sentiment
Bullish
ONCY Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $344.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 19.0%
Last 30 Days ▲ 19.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
63.07%
12-Months-Change
Fundamentals
Return on Equity
-745.62%
Trailing 12-Months
Asset Growth
-39.74%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
ONCY Stock 12 Month Forecast
Average Price Target
$6.67
▲(535.24% Upside)
Technical Analysis
Atossa Therapeutics
―
Oramed Pharm
―
Atara Biotherapeutics
―
Zentalis Pharmaceuticals
―
Prelude Therapeutics
―
Ownership Overview
2.53% Insiders
0.06% Mutual Funds
0.73% Other Institutional Investors
96.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---